Meyahealth
HomeGeneticsGeneOTX2 gene
Back to Gene
OTX2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

OTX2 gene

The OTX2 gene provides instructions for a transcription factor that regulates early embryonic development, particularly regarding the eyes and brain.

Normal Function

The OTX2 gene provides instructions for making a protein called a transcription factor. Transcription factors attach to specific regions of DNA to help regulate the activity of other genes. OTX2 is part of a family of homeobox genes, which control the formation of many body structures during early embryonic development.

The OTX2 protein plays a critical role in the development of the eyes and related structures, such as the optic nerves. It is also involved in brain development, including the formation of the pituitary gland, which produces hormones that control growth, reproduction, and other critical body functions.

Health Conditions Related to Genetic Changes

Anophthalmia/Microphthalmia

Variants in the OTX2 gene can cause one or both eyes to be absent (anophthalmia) or underdeveloped and abnormally small (microphthalmia). These conditions may occur in isolation or as part of a syndrome (syndromic anophthalmia or microphthalmia) that may include:

  • Missing pieces of eye tissue (coloboma)
  • Intellectual disabilities
  • Abnormalities of the pituitary gland

Other disorders

Variants in the OTX2 gene may contribute to the otocephaly-dysgnathia complex, characterized by low-set ears, an absent or underdeveloped lower jaw, a small mouth, and an unusually small tongue. Research also suggests that OTX2 may play a role in the progression of aggressive forms of medulloblastoma, a childhood brain tumor. In these cases, the OTX2 protein may work with splicing factors to rearrange mRNA, allowing tumor cells to grow.

Other Names for This Gene

  • CPHD6
  • MCOPS5

Frequently Asked Questions

Because OTX2 is important for pituitary development, clinicians should assess growth hormone, thyroid‑stimulating hormone, ACTH, and gonadotropins. Baseline hormone panels, MRI of the sellar region, and periodic monitoring of growth velocity, puberty onset, and signs of adrenal insufficiency are recommended, even if the patient initially presents only with eye findings.
Yes. Genetic testing (usually a targeted gene panel or whole‑exome sequencing) can identify pathogenic variants in OTX2. A positive result confirms that the eye abnormality is due to a genetic cause, helps predict associated features (such as pituitary hormone deficiencies or coloboma), guides surveillance (e.g., endocrine evaluation), and provides accurate recurrence risk information for future pregnancies (typically autosomal‑dominant with 50 % chance if a parent carries the variant, or de‑novo in many cases).
Some studies link OTX2 over‑expression or specific mutations to aggressive medulloblastoma in children. While routine cancer screening is not standard for all OTX2 carriers, patients with a family history of medulloblastoma or who develop neurological symptoms (headaches, vomiting, balance problems) should undergo brain MRI and be evaluated by pediatric oncology.
Management is multidisciplinary. Early assessment by craniofacial surgeons, ENT specialists, and speech therapists is essential. Surgical reconstruction of the mandible, ear reconstruction, and feeding support (often via gastrostomy) may be needed. Regular audiology and speech‑language evaluations help address hearing loss and speech development.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ